Page last updated: 2024-08-23

paclitaxel and Adenocarcinoma, Endometrioid

paclitaxel has been researched along with Adenocarcinoma, Endometrioid in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (5.56)	18.2507
2000's	33 (36.67)	29.6817
2010's	45 (50.00)	24.3611
2020's	7 (7.78)	2.80

Authors

Authors	Studies
Chang, WH; Lai, WA; Lee, NR; Lee, WL; Shen, SH; Wang, PH; Yang, ST	1
Bixel, K; Brady, MF; Burger, RA; Casey, AC; Cosgrove, C; duPont, NC; Enserro, D; Fujiwara, K; Monk, BJ; Moxley, K; Rubin, S; Soper, J; Tewari, KS; Thaker, P; Wahner Hendrickson, AE; Walker, JL	1
Chen, JR; Hung, SM	1
He, D; Li, L; Qu, X; Wang, Y	1
Li, S; Zhu, Z	1
Aubrey, C; Glaze, S; Köbel, M; Mattatall, F; Nelson, G; Saad, N	1
Backes, F; Birrer, MJ; Devor, EJ; Filiaci, V; Fleming, GF; Gonzalez-Bosquet, J; Guntupalli, S; Hanjani, P; Leslie, KK; McDonald, M; Miecznikowski, J; Ramirez, N; Reyes, HD; Samuelson, MI; Stephan, JM; Tewari, KS; Thiel, KW; Zhang, Y	1
Crim, A; Ding, K; Dvorak, J; Gillen, J; Greenwade, M; Gunderson, C; Moore, K; Rowland, M; Ruskin, R; Walter, A	1
Hong, JH; Khurelbaatar, T; Lee, JK; Lee, NW; Lee, S; Min, KJ; Ryu, KJ; Song, JY	1
Brown, L; Chen, AM; Ganju, RG; Hoover, A; Jewell, A; Tawfik, O; TenNapel, M	1
Asano, T; Hashimoto, S; Hirohashi, Y; Ikeo, K; Kanaseki, T; Kawai, N; Kubo, T; Kuroda, T; Mariya, T; Mizuuchi, M; Murai, A; Nakatsugawa, M; Saito, T; Tabuchi, Y; Torigoe, T; Tsukahara, T; Uno, S	1
Kimura, D; Masuda, T; Nakashima, Y; Narazaki, T; Ogawa, Y; Ohshima, K; Shiratsuchi, M; Takamatsu, A; Tsuda, M; Tsukamoto, Y	1
Allen, PK; Broaddus, RR; Chapman, BV; Eifel, PJ; Jhingran, A; Klopp, AH; Lu, KH; Ning, MS; Pardeshi, V; Soliman, PT; Swanick, CW; Westin, SN	1
Jang, JW; Lee, LJ	1
Deering, E; Grudem, M; Hendrickson, AW; Jatoi, A; Klampe, C; Smith, C	1
Ishibashi, T; Ishikawa, M; Ishikawa, N; Kurioka, H; Kyo, S; Minamoto, T; Nakamura, K; Nakayama, K; Nakayama, S; Ono, R; Onuma, H; Otsuki, Y; Razia, S; Yamashita, H	1
Ayeni, TA; Bakkum-Gamez, JN; Dowdy, SC; Haddock, MG; Keeney, GL; Long, HJ; Mariani, A; McGree, ME; Podratz, KC; Weaver, AL	1
Aquino-Parsons, C; Hoskins, P; Jutzi, L; Kwon, JS; Lim, P; Tinker, A	1
Borger, D; Bradford, LS; Clark, RM; Foster, R; Groeneweg, JW; Growdon, WB; Rauh-Hain, A; Rueda, BR; Zhang, L; Zukerberg, LR	1
Almirante, G; Bergamini, A; Candiani, M; Mangili, G; Taccagni, G; Viganò, P	1
Cho, CH; Cho, H; Kang, SB; Kim, BG; Kim, JH; Kim, SM; Nam, BH; Ryu, HS	1
Chen, JR; Yang, YC	1
Bertrand, M; Colombo, PE; Fabbro, M; Gutowski, M; Labaki, M; Mollevi, C; Mourregot, A; Quenet, F; Rouanet, P; Saint-Aubert, B	1
Abe, A; Kato, K; Kondo, E; Matoda, M; Nomura, H; Okamoto, S; Omatsu, K; Sueoka, K; Takeshima, N; Umayahara, K; Usami, T; Yamamoto, A	1
Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D	1
Chang-Halpenny, C; Hwang-Graziano, J; Lu, SM	1
Aziz, AB; Chishti, U	1
Chu, C; Lin, LL; Rubin, S; Xu, MJ	1
Bhamarapravatana, K; Mairaing, K; Piyawang, W; Poomtavorn, Y; Suwannarurk, K; Tangtiang, K; Thaweekul, Y	1
Furukawa, N; Ito, F; Nakai, T	1
Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M	1
Cirik, DA; Karalok, A; Koc, S; Tasci, T; Tulunay, G; Turan, T; Ureyen, I	1
Kaido, Y; Kikuchi, A; Murakami, K; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S	1
Adams, N; Barve, M; Bergman, MK; Bognar, E; DeMars, LR; Fine, B; Fleming, EL; Goodman, H; Grosen, E; Hancock, KC; Heffernan, TP; Koon, EC; Kumar, P; Manning, L; Matthews, CM; Nemunaitis, J; Oh, J; Pappen, BO; Senzer, N; Spitz, DL; Wallraven, G; West, L	1
Alvarez-Secord, A; Copeland, LJ; Creasman, WT; Hanjani, P; Java, JJ; Kesterson, JP; Morgan, MA; Morris, RT; Rose, PG; Stehman, FB; Warshal, DP	1
Alvarez Secord, A; Armstrong, DK; Cohn, DE; Copeland, LJ; Garcia-Soto, AE; Java, JJ; Lele, SB; Nieves Neira, W; Pearson, JM; Tewari, KS; Walker, JL	1
Bell, J; Chan, JK; Fuh, K; Herzog, T; Java, JJ; Kapp, DS; Monk, BJ; Young, R	1
Chong, QY; Ding, K; Kong, X; Li, R; Li, X; Lobie, PE; Ma, L; Pandey, V; Qian, P; Wu, Z; Xiong, Z; Yang, Y; Yuan, Y; Zhu, T	1
Ding, H; Liu, FY; Tang, L; Xiong, Y; Zheng, M	1
Hoskins, PJ; Le, N; Mazgani, M	1
Chauffert, B; Combe, M; Delroeux, D; Demarchi, M; Guardiola, E; Heyd, B; Lorgis, V; Pivot, X; Royer, B; Stein, U	1
Amant, F; Berteloot, P; Capoen, A; Leunen, K; Moerman, P; Neven, P; Van Calster, B; Vandenput, I; Vergote, I	1
Bell, J; Chan, JK; Fleming, GF; Herzog, TJ; Kapp, DS; Monk, BJ; Tian, C	1
Busci, L; Carlini, L; Cipriani, S; De Marzi, P; Frigerio, L; Mangili, G; Parazzini, F; Viganò, R	1
Chen, N; Jiang, T; Kong, B; Wang, XJ; Zhang, DD; Zhao, F; Zheng, W	1
Chung, HH; Kang, SB; Kim, HS; Kim, JW; Lee, HP; Park, NH; Song, YS; Wu, HG	1
Correa, R; Hoskins, PJ; Le, N	1
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D	1
Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y	1
Broaddus, R; Habra, MA; Jimenez, C; Khan, MI; Waguespack, SG	1
Gregoriou, O; Grigoriadis, C; Iavazzo, C; Kondi-Pafiti, A; Papakonstantinou, E; Salakos, N	1
Cho, KR; Fearon, ER; Hu, TC; Rehemtulla, A; Wu, R	1
Itamochi, H; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Sato, S; Shimada, M	1
Dong, L; Duan, T; Feng, Y; Zhang, Z; Zhou, Q; Zhu, Y	1
Byron, SA; Loch, DC; Pollock, PM	1
Kanakura, Y; Kometani, K; Nakazawa, K; Niwa, K; Sekiya, T	1
Akhan, SE; Bengisu, E; Berkman, S; Işikoglu, M; Salihoglu, Y	1
Ficorella, C; Marchetti, P; Narducci, F; Paris, I; Porzio, G; Ricevuto, E	1
Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T	1
Inoue, H; Kikuchi, Y; Kita, T; Kudoh, K; Oogi, S; Yamamoto, K	1
Atallah, D; Camatte, S; Castaigne, D; Duvillard, P; Joulie, F; Lhommé, C; Morice, P; Pautier, P; Rey, A; Thoury, A	1
Balat, O	1
Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A	1
Daraï, E; Dormont, D; Madelenat, P; Zylberberg, B	1
Kagami, T; Onoda, C; Tohya, T; Yoshimura, T	1
Ino, K; Kajiyama, H; Kikkawa, F; Kondo, C; Mizokami, Y; Mizutani, S; Nomura, S; Shibata, K	1
Atabekoglu, C; Berker, B; Bilgin, T; Dunder, I	1
Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J	1
Acikalin, MF; Ozalp, S; Peker, B; Yalcin, OT	1
Akizuki, S; Andoh, M; Fujiwara, Y; Katsumata, N; Watanabe, T; Yamanaka, Y	1
Aki, T; Asada, M; Enomoto, T; Ikegami, H; Ito, K; Kameda, T; Kuragaki, C; Mizutani, T; Murata, Y; Nagamatsu, M; Nakashima, R; Nishizaki, T; Otsuki, Y; Sugita, N; Ueda, Y; Ueno, Y; Wakimoto, A; Yamada, T; Yamazaki, M; Yoshino, K	1
Haruta, S; Kanayama, S; Kawaguchi, R; Kobayashi, H; Tanase, Y; Yamada, Y	1
Vapattanawong, P	1
Hasegawa, T; Matsui, K; Ohta, S; Tateno, M; Yamakawa, Y	1
Baki, M; Bodoky, G; Cseh, J; Csejtei, A; Csömör, S; Dank, M; Erfán, J; Esik, O; Faluhelyi, Z; Hernádi, Z; Izsó, J; Kammerer, K; Kásler, M; Magyar, T; Mayer, A; Megyery, E; Moskovits, K; Pécsi, L; Pikó, B; Pintér, T; Pulay, T; Ruzsa, A; Szánthó, A; Szántó, I; Szántó, J; Szucs, M; Tálos, Z; Thurzó, L	1
Kanamori, T; Kawashima, T; Murakami, H; Nakamura, Y	1
Ino, K; Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Terauchi, M; Umezu, T	2
Maxwell, GL; McGuire, WP; Muggia, F; Rose, GS; Rose, PG; Rubin, SC; Sundborg, MJ; Tian, C; Winter, WE	1
Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K	1
Colombo, N; Fossati, R; Fruscio, R; Garbi, A; Ieda', N; Lissoni, AA; Mangioni, C; Torri, V	1
Brard, L; Charbonneau, N; Disilvestro, P; Dizon, DS; Granai, CO; Hughes, T; Legare, R; Lomme, M; Restivo, A; Weitzen, S	1
Beller, U; Hiller, N; Hornreich, G; Lavie, O; McDaniel, C; Neuman, M; Winograd, B	1
Goldberg, JM; Hempling, RE; Piver, MS; Recio, FO	1
Aghajanian, C; Fennelly, D; McKenzie, M; Norton, L; O'Connor, C; O'Flaherty, C; Shapiro, F; Spriggs, D; Tong, W	1
Labovich, TM	1
Canuti, D; Galli, I; Oliverio, G; Panzini, I; Ravaioli, A; Scarpellini, M; Tononi, A	1
Ishikawa, H; Kuzuya, K; Nakanishi, T; Nawa, A; Suzuki, Y	1
Arii, Y; Fujimura, H; Furuhashi, Y; Hattori, S; Ishikawa, H; Iwase, A; Kawai, M; Kikkawa, F; Kuzuya, K; Mizutani, S; Nakanishi, T; Nawa, A; Sakakibara, K; Sasayama, E; Suzuki, T	1

Reviews

5 review(s) available for paclitaxel and Adenocarcinoma, Endometrioid

Article	Year
Scalp metastasis from endometrial carcinoma: a case report and literature review. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2018, Volume: 38, Issue:8 Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Endometrioid; Consolidation Chemotherapy; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Head and Neck Neoplasms; Humans; Hysterectomy; Liver Neoplasms; Middle Aged; Obesity; Paclitaxel; Salpingo-oophorectomy; Scalp; Skin Neoplasms	2018
Endometriosis-associated tumor at the inguinal site: report of a case diagnosed during pregnancy and literature review. The journal of obstetrics and gynaecology research, 2014, Volume: 40, Issue:4 Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Endometriosis; Female; Female Urogenital Diseases; Humans; Inguinal Canal; Labor, Induced; Paclitaxel; Pelvic Pain; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Premature Birth; Prenatal Diagnosis; Treatment Outcome	2014
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review. Journal of ovarian research, 2016, Aug-11, Volume: 9, Issue:1 Topics: Adult; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Squamous Cell; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Analysis	2016
Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review. European journal of gynaecological oncology, 2005, Volume: 26, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cyclophosphamide; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Gynecologic Surgical Procedures; Humans; Mixed Tumor, Malignant; Neoplasm Staging; Paclitaxel; Treatment Outcome	2005
Acute hypersensitivity reactions to chemotherapy. Seminars in oncology nursing, 1999, Volume: 15, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Drug Hypersensitivity; Female; Humans; Middle Aged; Oncology Nursing; Ovarian Neoplasms; Paclitaxel	1999

Trials

15 trial(s) available for paclitaxel and Adenocarcinoma, Endometrioid

Article	Year
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecologic oncology, 2022, Volume: 164, Issue:2 Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Ethnicity; Fallopian Tube Neoplasms; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; White People	2022
A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: a Korean Gynecologic Oncologic Group study. International journal of radiation oncology, biology, physics, 2014, Sep-01, Volume: 90, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Chemoradiotherapy; Confidence Intervals; Disease-Free Survival; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Prospective Studies; Radiation-Sensitizing Agents; Republic of Korea; Survival Analysis	2014
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecologic oncology, 2016, Volume: 143, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carboplatin; Carcinoma, Endometrioid; Cross-Over Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; T-Lymphocytes	2016
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology, 2016, Volume: 143, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Reoperation; Survival Rate	2016
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecologic oncology, 2010, Volume: 116, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Risk Factors; Survival Rate	2010
Adjuvant treatment with concomitant radiotherapy and chemotherapy in high-risk endometrial cancer: a clinical experience. Gynecologic oncology, 2010, Volume: 116, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Risk Factors; Survival Rate	2010
Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. European journal of gynaecological oncology, 2004, Volume: 25, Issue:2 Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Second-Look Surgery; Treatment Outcome	2004
Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary. European journal of gynaecological oncology, 2004, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Salvage Therapy; Treatment Outcome	2004
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. European journal of gynaecological oncology, 2004, Volume: 25, Issue:3 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; France; Humans; Ifosfamide; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome	2004
Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European journal of gynaecological oncology, 2005, Volume: 26, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carcinoma, Endometrioid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Radiography; Salvage Therapy; Survival Analysis; Treatment Outcome; Turkey	2005
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. British journal of cancer, 2008, Feb-26, Volume: 98, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Epirubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors	2008
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel	1997
Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of chemotherapy (Florence, Italy), 1999, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life; Treatment Outcome	1999
3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International journal of clinical oncology, 2001, Volume: 6, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Predictive Value of Tests; Treatment Outcome	2001
Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study. International journal of clinical oncology, 2001, Volume: 6, Issue:6 Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome	2001

Other Studies

70 other study(ies) available for paclitaxel and Adenocarcinoma, Endometrioid

Article	Year
Endometriosis-associated epithelial ovarian cancer is a more complicated disease than we suspected before. Taiwanese journal of obstetrics & gynecology, 2021, Volume: 60, Issue:6 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Cisplatin; Endometriosis; Female; Humans; Laparotomy; Middle Aged; Ovarian Cysts; Ovarian Neoplasms; Paclitaxel; Treatment Outcome	2021
Exceptional widespread, life threatening lung metastasis in stage IA ovarian endometrioid carcinoma: A case report. Taiwanese journal of obstetrics & gynecology, 2022, Volume: 61, Issue:5 Topics: Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2022
Integrative Analysis Reveals a Nine TP53 Pathway-Related lncRNA Prognostic Signature in Endometrial Cancer. BioMed research international, 2022, Volume: 2022 Topics: Biomarkers, Tumor; Carcinoma, Endometrioid; Cisplatin; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Prognosis; RNA, Long Noncoding; Tumor Suppressor Protein p53	2022
Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery. Journal of ovarian research, 2020, Aug-09, Volume: 13, Issue:1 Topics: Adult; Age Factors; Aged; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Female; Humans; Logistic Models; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Propensity Score; SEER Program; Survival Analysis	2020
Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. Gynecologic oncology, 2021, Volume: 161, Issue:2 Topics: Adult; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Female; Humans; Male; Ovarian Neoplasms; Paclitaxel; Receptors, Androgen; Salpingo-oophorectomy; Sex Reassignment Procedures; Testosterone; Transgender Persons	2021
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecologic oncology, 2017, Volume: 146, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Immunohistochemistry; Middle Aged; Neoplasm Staging; Paclitaxel; Piperidines; Prognosis; Retrospective Studies; Stathmin; Survival Rate	2017
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecologic oncology, 2017, Volume: 146, Issue:2 Topics: Adenocarcinoma, Clear Cell; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2017
Undifferentiated Endometrial Carcinomas: Clinicopathologic Characteristics and Treatment Outcomes. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2018, Volume: 28, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Lymph Nodes; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate	2018
Clonal analysis revealed functional heterogeneity in cancer stem-like cell phenotypes in uterine endometrioid adenocarcinoma. Experimental and molecular pathology, 2019, Volume: 106 Topics: Animals; Carboplatin; Carcinoma, Endometrioid; Clone Cells; Culture Media; DNA, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplastic Stem Cells; Paclitaxel; Phenotype; Sequence Analysis, DNA; Serum; Spheroids, Cellular; Tumor Cells, Cultured	2019
Transformation of follicular lymphoma to double-hit lymphoma during adjuvant chemotherapy for concurrent ovarian carcinoma. International journal of hematology, 2019, Volume: 110, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Female; Humans; Lymphoma, Follicular; Middle Aged; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel	2019
Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecologic oncology, 2019, Volume: 154, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Treatment Outcome	2019
External Beam, Brachytherapy, or Chemotherapy? Defining Adjuvant Therapy for Early-Stage and High- and High-Intermediate-Risk Endometrial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 07-20, Volume: 37, Issue:21 Topics: Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Paclitaxel	2019
Loratadine for Paclitaxel-Induced Myalgias and Arthralgias. The American journal of hospice & palliative care, 2020, Volume: 37, Issue:3 Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Arthralgia; Carcinoma, Endometrioid; Female; Humans; Loratadine; Middle Aged; Myalgia; Ovarian Neoplasms; Paclitaxel	2020
Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies). International journal of molecular sciences, 2019, Jul-31, Volume: 20, Issue:15 Topics: Aged; Antibodies, Neutralizing; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cisplatin; DNA Mismatch Repair; Doxorubicin; Endometrial Neoplasms; Female; Gene Expression; Humans; Immunophenotyping; Lymphocytes, Tumor-Infiltrating; Microsatellite Instability; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor	2019
Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecologic oncology, 2013, Volume: 129, Issue:3 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms	2013
The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma. Gynecologic oncology, 2013, Volume: 131, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate	2013
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecologic oncology, 2014, Volume: 133, Issue:2 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Class I Phosphatidylinositol 3-Kinases; Endometrial Neoplasms; Female; Humans; Mice; Mice, SCID; Morpholines; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2014
Spontaneous pneumothorax after intensive chemotherapy in endometrial cancer: a rare complication. Taiwanese journal of obstetrics & gynecology, 2014, Volume: 53, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Lung Neoplasms; Paclitaxel; Pneumothorax; Remission Induction	2014
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecologic oncology, 2014, Volume: 135, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome; Young Adult	2014
Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Ifosfamide; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Para-Aortic Bodies; Pelvic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult	2015
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. American journal of obstetrics and gynecology, 2015, Volume: 212, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models	2015
Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma. Gynecologic oncology, 2015, Volume: 137, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cisplatin; Disease Progression; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome	2015
Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women. JPMA. The Journal of the Pakistan Medical Association, 2015, Volume: 65, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Endometrioid; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Pakistan; Postoperative Complications; Retrospective Studies; Treatment Outcome	2015
Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. American journal of clinical oncology, 2017, Volume: 40, Issue:6 Topics: Abdominal Neoplasms; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Chemoradiotherapy; Cohort Studies; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pelvic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Burden	2017
Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2015, Volume: 98 Suppl 3 Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Endometrioid; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitals, University; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Remission Induction; Thailand; Treatment Outcome	2015
Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:2 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Receptor, ErbB-2; Retrospective Studies	2016
Singapore Cancer Network (SCAN) Guidelines for the Systemic Therapy of Endometrial (Uterine) Cancer. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Progestins; Singapore; Sirolimus; Tamoxifen	2015
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy? European journal of gynaecological oncology, 2016, Volume: 37, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies	2016
Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy? European journal of gynaecological oncology, 2016, Volume: 37, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Salpingectomy	2016
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecologic oncology, 2016, Volume: 143, Issue:3 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Time Factors	2016
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. Gynecologic oncology, 2016, Volume: 143, Issue:3 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Survival Rate; Time Factors	2016
Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy. Endocrinology, 2017, 06-01, Volume: 158, Issue:6 Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Endometrioid; Cell Proliferation; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Prolactin; Tumor Cells, Cultured	2017
[Clinical characteristics and prognosis of epithelial ovarian cancer in young women]. Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Tumor Burden; Young Adult	2008
Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience. Gynecologic oncology, 2008, Volume: 111, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Papillary; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Paclitaxel; Retrospective Studies; Risk Factors	2008
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World journal of surgical oncology, 2009, Feb-09, Volume: 7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystadenocarcinoma, Serous; Feasibility Studies; Female; Humans; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Treatment Outcome	2009
Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? British journal of cancer, 2009, Jul-21, Volume: 101, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies	2009
High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer research, 2010, Jul-01, Volume: 70, Issue:13 Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Carcinoma, Endometrioid; Cell Growth Processes; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Mice; Mice, SCID; Middle Aged; NF-E2-Related Factor 2; Paclitaxel; RNA, Messenger; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays	2010
Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cisplatin; Databases, Factual; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome	2010
CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer. Gynecologic oncology, 2011, Volume: 120, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Endometrioid; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Treatment Outcome	2011
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11 Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan	2010
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncology reports, 2011, Volume: 25, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transforming Growth Factor beta1	2011
Acute-onset ectopic adrenocorticotropic hormone syndrome secondary to metastatic endometrioid carcinoma of the ovaries as a fatal complication. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16 Topics: ACTH Syndrome, Ectopic; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Fatal Outcome; Female; Humans; Liver Neoplasms; Ovarian Neoplasms; Paclitaxel	2011
Clinicopathological characteristics of ovarian carcinomas associated with endometriosis. Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Endometriosis; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Salpingectomy	2012
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-01, Volume: 17, Issue:23 Topics: Animals; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Female; Humans; Mice; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Wnt Signaling Pathway	2011
Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma. Gynecologic and obstetric investigation, 2012, Volume: 73, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome	2012
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. The journal of obstetrics and gynaecology research, 2012, Volume: 38, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Evaluation, Preclinical; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoglycemic Agents; Lactoylglutathione Lyase; Metformin; Paclitaxel	2012
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; Female; Humans; Mutation; Paclitaxel; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor; Tumor Cells, Cultured	2012
Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin. International journal of clinical oncology, 2002, Volume: 7, Issue:3 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Endometrioid; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Japan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Radiography, Thoracic; Remission Induction; Time Factors; Tomography, X-Ray Computed; Uterine Hemorrhage	2002
Brain metastasis of ovarian cancer after negative second-look laparotomy. European journal of gynaecological oncology, 2002, Volume: 23, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Female; Humans; Laparoscopy; Magnetic Resonance Imaging; Middle Aged; Ovarian Neoplasms; Paclitaxel; Radiography; Second-Look Surgery	2002
Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. European journal of gynaecological oncology, 2002, Volume: 23, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cisplatin; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Skin Tests	2002
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids	2003
Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients. Current medicinal chemistry, 2004, Volume: 11, Issue:4 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Endometrioid; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Reoperation	2004
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. European journal of gynaecological oncology, 2004, Volume: 25, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53	2004
[Successful treatment of endometrial carcinoma associated with lung metastasis by paclitaxel and carboplatin chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lung Neoplasms; Lymph Node Excision; Paclitaxel; Pelvis; Postoperative Care; Prognosis	2004
Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma. Gynecologic oncology, 2004, Volume: 95, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Endometrioid; Cell Line, Tumor; Cisplatin; Cystinyl Aminopeptidase; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Transfection	2004
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate	2005
Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. International journal of clinical oncology, 2005, Volume: 10, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome	2005
Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer letters, 2006, Sep-28, Volume: 241, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Genes, p53; Humans; Microsatellite Repeats; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Survival Rate	2006
[Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Hysterectomy; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Uterine Neoplasms	2006
A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies	2006
[Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Umbilicus	2007
[The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003]. Orvosi hetilap, 2006, Dec-31, Volume: 147, Issue:52 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brenner Tumor; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Hungary; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Treatment Outcome	2006
[A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; CA-125 Antigen; Camptothecin; Carcinoma, Endometrioid; Cisplatin; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Laparotomy; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids	2007
Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity. Human cell, 2007, Volume: 20, Issue:3 Topics: Animals; Antineoplastic Agents; CA-125 Antigen; Carboplatin; Carcinoma, Endometrioid; Cell Division; Cell Line, Tumor; Chromosomes, Human; Cisplatin; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel	2007
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-01, Volume: 26, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Medical Records; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Postoperative Complications; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate	2008
Carbon beam therapy in recurrent ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy	2008
Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2008, Volume: 27, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Tubulin	2008
For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? American journal of clinical oncology, 2008, Volume: 31, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate	2008
Extra-pelvic metastasis of endometrioid carcinoma; resistance to chemo-radiation therapy--response to paclitaxel treatment. Case report. European journal of gynaecological oncology, 1995, Volume: 16, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel	1995
Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecologic oncology, 1996, Volume: 63, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Salvage Therapy	1996